TG Therapeutics TGTX Purchases of fixed maturity securities
Purchases of fixed maturity securities at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's purchases of fixed maturity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's purchases of fixed maturity securities?
- TG Therapeutics (TGTX) reported purchases of fixed maturity securities of $21.06M in Q1 2026.
- How has TG Therapeutics's purchases of fixed maturity securities changed year-over-year?
- TG Therapeutics's purchases of fixed maturity securities decreased by 77.1% year-over-year, from $92.06M to $21.06M.
- What is the long-term trend for TG Therapeutics's purchases of fixed maturity securities?
- Over 3 years (2021 to 2025), TG Therapeutics's purchases of fixed maturity securities has grown at a 58.8% compound annual growth rate (CAGR), from $55.53M to $222.24M.
- What does purchases of fixed maturity securities mean?
- Cash spent to buy bonds or other fixed-income investments.
- How do you interpret purchases of fixed maturity securities?
- Higher outflows indicate active deployment of cash into conservative, interest-earning assets.
- How does purchases of fixed maturity securities compare across companies?
- Standard for firms managing large cash balances or insurance floats.